<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472858</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001/Donafenib-101</org_study_id>
    <nct_id>NCT04472858</nct_id>
  </id_info>
  <brief_title>A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter,Open-label,Dose-Escalation and Expansion Study of CS1001 in Combination With Donafenib in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics and treatment effect of&#xD;
      CS1001 in combination with Donafenib in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trail uses an open, multi-center study design, Contains two parts: a dose escalation&#xD;
      part and a dose expansion part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the dose limiting toxicity (DLT)</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose(MTD)</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the recommended dose of phase II</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate as determined by the Invertigator using RECIST V1.1</measure>
    <time_frame>In the dose escalation part, from the day of first dose to 21 days after last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-CS1001 antibody</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>From the day of first dose to 21 days after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cholangiocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholangiocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Squamous cell carcinoma of the head and neck（HNSCC）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib</intervention_name>
    <description>dose escalation: Donafenib 100 mg QD/100 mg BID/200 mg BID (p.o.). dose expansion: Patients will be assigned to specific tumor types and treated at the recommended dose for dose escalation.The recommended dose for dose escalation will be determined by the dose escalation study.</description>
    <arm_group_label>Cholangiocarcinoma</arm_group_label>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>CS1001 will be administrated by intravenous (i.v.) infusion once every 28 days</description>
    <arm_group_label>Cholangiocarcinoma</arm_group_label>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fully understand this study and voluntarily sign ICF;&#xD;
&#xD;
          -  18 to 75 years old (including 18 and 75 years old), male or female;&#xD;
&#xD;
          -  Subjects with advanced solid tumors, including:&#xD;
&#xD;
        Phase I study:&#xD;
&#xD;
        subjects with advanced solid tumors confirmed by histology or cytology that are not&#xD;
        suitable for surgical resection, or have failed or tolerated standard treatment, or have no&#xD;
        standard treatment. Including but not limited to Cholangiocarcinoma , head and neck&#xD;
        squamous cell carcinoma (HNSCC) and endometrial cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of active autoimmune diseases or autoimmune diseases; patients with&#xD;
             vitiligo or asthma that has been completely relieved in childhood, and patients who do&#xD;
             not need any intervention after adulthood can be included;&#xD;
&#xD;
          -  Participants with any condition that impairs their ability to take oral medication,&#xD;
             such as lack of physical integrity of the upper gastrointestinal tract or&#xD;
             malabsorption syndrome.&#xD;
&#xD;
          -  Patients with uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
             requiring repeated drainage and need to retain a catheter;&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) antibody positive;&#xD;
&#xD;
          -  Patients who are simultaneously infected with hepatitis B virus and hepatitis C virus;&#xD;
&#xD;
          -  Lactating women. If they are willing to stop breastfeeding, they can also be included&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ye Guo, MD</last_name>
    <phone>13501678472</phone>
    <email>pattrickguo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Eastern Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Guo, MD</last_name>
      <phone>13501678472</phone>
      <email>pattrickguo@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

